阿托伐他汀对尿毒症非透析患者白细胞介素-6及高敏C反应蛋白的影响

Effects of atovastation on interleukin-6 and high sensitivity C-reactive protein in nondialysed patients with uremia

目的探讨阿托伐他汀对尿毒症非透析患者白细胞介素-6(interleukin-6,IL-6)和高敏C反应蛋白(highsensitivity C-reactive protein,hs-CRP)的影响。方法 72例尿毒症非透析患者随机分成他汀治疗组39例和常规治疗组33例,同期20例体检健康者为对照组,他汀治疗组每晚口服阿托伐他汀20mg,常规治疗组不给予调酯药,观察治疗组治疗前、治疗后12,24周空腹血清IL-6和hs-CRP的变化,并与对照组进行比较。结果与对照组比较,治疗前他汀治疗组与常规治疗组血清IL-6和hs-CRP水平明显升高(P<0.05),血浆前白蛋白、白蛋白、血红蛋白均明显降低(P<0.05);治疗12周后,他汀治疗组IL-6和hs-CRP水平较治疗前下降(P<0.05),治疗24周后较治疗12周后明显下降(P<0.05);他汀治疗组血浆前白蛋白、白蛋白、血红蛋白高于治疗前及同期常规治疗组(P<0.05);血肌酐、尿素氮低于治疗前及同期常规治疗组(P<0.05)。结论应用阿托伐他汀可抑制尿毒症非透析患者的微炎症反应,改善患者营养状态。

Objective To investigate the therapeutic effect of atovastation on interleukin-6 （IL 6） and high sensitivity C- reactive protein （hs-CRP） in nondialysed patients with uremia. Methods Seventy-two nondialysed patients with uremia were randomly divided into atovastation group （n= 39） and routine treatment group （n= 33）. Another twenty healthy volunteers were as controls （control group）. The atovastation group was given 20 mg at night once daily for 24 weeks, and the routine treatment group did not take antihyperlipidernic drugs. The levels of fasting IL-6 and hs-CRP and the reactions of patients were observed before treatment, and in 12 and 24 weeks after treatment. Results The levels of IL-6 and hs-CRP were higher, and serum prealburnin, albumin and hemoglobin were lower before treatment in atovastation group and routine treatment group than those in control group （P（0.05）. The levels of IL-6 and hs-CRP were lower in 12-week treatment than those before treatment （P〈0.05）, and were lower in 24 week treatment than those in 12-week treatment （P〈0.05） in atovastation group. The levels of albumin, prealbumin and hemoglobin were higher after treatment than those before treatment, as well as those in routine treatment group （P〈0.05）. Serum creatnine and urea nitrogen were lower in atovastation group than those in routine treatment group （P〈0.05）. Conclusion Atovastation relieves the microinflamrnation reactions and improves nutritional status in nondialysed patients with uremia.